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ARTICLE OPEN
Aflibercept in clinical practice; visual acuity, injection numbers
and adherence to treatment, for diabetic macular oedema in 21
UK hospitals over 3 years
S. J. Talks 1✉, I. Stratton 2, T. Peto 3, A. Lotery 4, U. Chakravarthy 3, H. Eleftheriadis5, S. Izadi6, N. Dhingra7, P. Scanlon 2 and
the UK Aflibercept Users’ Group*
© The Author(s) 2021
INTRODUCTION: Randomised controlled trials provide evidence that a treatment works. Real world evidence is required to assess if
proven treatments are effective in practice.
METHOD: Retrospective data collection on patients given aflibercept for diabetic macular oedema over 3 years from 21 UK
hospitals: visual acuity (VA); Index of multiple deprivation score (IMD); injection numbers; protocols used, compared as a cohort and
between sites.
RESULTS: Complete data: 1742 patients (from 2196 eligible) at 1 year, 860 (from 1270) at 2, 305 (from 506) at 3 years. The median
VA improved from 65 to 71, 70, 70 (ETDRS letters) at 1, 2 and 3 years with 6, 9 and 12 injections, respectively. Loss to follow-up: 10%
1 year, 28.8% at 3. Centres varied: baseline: mean age 61–71 years (p < 0.0001); mean IMD score 15–37 (p < 0.0001); mean VA 49–68
(p < 0.0001). Only four centres provided a loading course of five injections at monthly intervals and one 6. This did not alter VA
outcome at 1 year. Higher IMD was associated with younger age (p= 0.0023) and worse VA at baseline (p < 0.0001) not total
number of injections or change in VA. Lower starting VA, higher IMD and older age were associated with lower adherence (p=
0.0010).
CONCLUSIONS: The data showed significant variation between treatment centres for starting age, VA and IMD which influenced
adherence and chances of good VA. Once treatment was started IMD did not alter likelihood of improvement. Loading dose
intensity did not alter outcome at one year.
Eye; https://doi.org/10.1038/s41433-021-01625-8
INTRODUCTION
Randomised controlled trials provide evidence of the efficacy of a
treatment. Real world evidence (RWE) assesses the effectiveness of
a treatment when introduced into routine clinical practice [1]. For
anti-vascular endothelial growth factor (anti-VEGF) treatment, RWE
can be used for measuring outcomes such as numbers of
injections given over time and adherence to follow-up. In addition,
RWE can be used to compare centres for patient population
characteristics and treatment provision in order to provide
evidence enabling service improvements [2]. On the contrary,
comparing VA outcomes for different treatment regimes, using
multi-centre data collection might not be as robust due to
influences such as service capacity, clinician choice, patient
adherence and payer requirements.
The VIVID and VISTA studies showed that treatment with
aflibercept, an anti-VEGF, in a clinical setting resulted in a mean
visual acuity (VA) gain of 10 ETDRS (Early Treatment Diabetic
Retinopathy Study) letters, from a mean baseline of 60 letters, at 1
year, in eyes with DME [3]. This was similar to that seen in the RISE
and RIDE studies for ranibizumab [4]. In the VIVID and VISTA trials,
five injections were given a month apart then 2 monthly for a year,
forming the basis of aflibercept’s posology in DME. In Protocol T of
DRCR.net, initially four injections were given 4 weeks apart
supplemented by two more injections 4 weeks apart if DME was
still present [5], leading to some clinicians promoting a protocol of
6 injections at 4 weekly intervals [5]. Previously published RWE in
the UK for ranibizumab found that, when compared to VIVID and
VISTA, the mean starting VA was lower at 51.2 letters and VA gains
modest, increasing to 54.2 and 52.5 letters at 1 and 2 years
respectively, but an average of only 3.3 injections were actually
given during the first year [6].
Ranibizumab was approved as a first-line treatment in the UK
for centre involving DME over 400 microns in 2012 and aflibercept
followed in 2015. Aflibercept has replaced ranibizumab as first-line
DME treatment in many centres. The aim of this study was to
assess the effectiveness of aflibercept in improving and preserving
vision in patients with DME in clinical practice over three years in
the UK.
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We assessed the number of injections given, initial treatment
protocols used, changes in VA and adherence to treatment in a
multicentre cohort of patients and specifically examined differ-
ences between centres. To assess potential differences between
patient populations in participating centres we correlated this
with the index of multiple deprivation score (IMD), mean age,
mean duration of diabetes, proportion of diabetes type, and mean
baseline VA. In addition, we used survival analysis as a means of
assessing outcomes which is less affected by annual time points
and loss to follow-up [7].
METHODS
Relevant anonymised data of DME patients undergoing aflibercept
injections from 21 UK hospitals that used a dedicated ophthalmology
electronic patient record system (Medisoft Ophthalmology, Medisoft
Limited, Leeds, UK) was exported in December 2019. If both eyes were
treated, only data from the first eye to be treated were included; for those in
whom treatment was commenced simultaneously in both eyes, the eye with
better VA was used. Cases were excluded from analysis If additional
pharmaceutical therapy had been given. All data from patients who had a
baseline VA measurement and the potential for 1, 2 or 3 years of follow-up
was accounted for. Included in the 1, 2 and 3-year VA outcome analysis were
those who had, both baseline VA and a VA measurement within 8 weeks of
the specified year point and a further measurement beyond that year point.
The lead clinician and Caldicott Guardian (responsible nominee for data
protection) at each NHS hospital gave written approval for anonymised
data extraction. Anonymized database analyses of this type do not require
ethical permission as they are viewed as service evaluation. This study was
conducted in accordance with the Declaration of Helsinki 2013 and the
United Kingdom’s Data Protection Act 2018.
VA records are entered as ETDRS letter scores at 2 m in the EMR system.
At each visit, the best-measured VA value was used in the analysis, usually
with a habitual correction rather than refraction, as this is routine clinical
practice. VA of count fingers, hand movements, perception of light (PL)
and no PL were substituted with a value of 0 letters. Both the mean and
median values are reported in this study as the data are unlikely to be
normally distributed, and the median is less influenced by outliers, such as
very low VA in patients with vitreous haemorrhage.
Linear regression was used to relate VA change over 12 months from the
first injection with age (grouped <65 years, 65–74, 75 and above), baseline
letter score (<50 letters, 50–59, 60–69, 70–79, 80 or more), and number of
injections. The Cox proportional hazards model was used for survival
analysis of time to VA improvement in relation to injection numbers and
time to lost to follow-up.
The number of patients completing an initial course of 3, 5 and
6 monthly injections was analysed and total number of injections per
treatment regime used was compared between centres.
In the UK deprivation is measured using the IMD [8]. The relationship
between IMD and the age of presentation, VA, number of injections given
and adherence to follow-up was assessed.
All statistical analyses were carried out using SAS 9.4. Descriptive
statistics for baseline characteristics were obtained using PROC MEANS and
PROC FREQ and plots done with PROC GPLOT. Time to event data was
analysed using PROC LIFETEST and PROC PHREG.
RESULTS
In total 2196 patients at the 21 sites had an aflibercept injection
for DME at least 1 year prior to data extraction and had a baseline
VA measurement, being eligible for 1-year follow-up. Of these, 226
had no data at or beyond 1 year (10%). An additional 228 had no
data within 8 weeks of the anniversary. Altogether 1742 were
analysed for the 1-year outcomes. Corresponding numbers for
year 2 and 3 are given in Table 1.
There was no significant heterogeneity between centres in
duration of diabetes (mean 15–19 years, p= 0.68). The majority
had type 2 diabetes (86%) and 62% were male (Table 2).
There was significant heterogeneity between centres for
baseline age (61–71 (p < 0.0001)), IMD score (mean 15–37 (p <
0.0001), and VA (49–68 letters p < 0.0001). Deaths were recorded
in 119 cases, varying from 0% to 7.5% between centres.
The 1742 patients in the 1-year cohort had a median age of 64
years (56–73 years; 25th to 75th centile), mean baseline VA 62
(ETDRS) letters (median 65; (Inter Quartile Range IQR 55 to 74),
improving by 5 letters (IQR-1 to 12) to a mean of 67, median of 71
(IQR 60–78), after a median of 6 (IQR 5 to 8) injections. Worse
baseline VA was associated with the greatest improvement in VA
(p < 0.001), those with fewer than 50 letters at baseline having
improved 13.9 letters (19.3 mean standard deviation (SD)) and
those with 80 letters or more losing 3.2 (7.0 SD) letters.
The 860 patients with 2-year data had a median baseline VA of
65 letters (IQR 54-72) and median VA at 2 years of 70 (IQR 60–78)
after a median of 9 (6–11) injections.
For the 305 patients with 3 years of follow-up, the median VA at
baseline was 65 (IQR 55 to 72) and at 3 years 70 (IQR 60–77), after
a median of 12 (IQR 7–16) injections. The median OCT thickness
reduced from 441(IQR 394–506) to 283 μm at 3 years, (IQR 241
to 316).
Older patients had a smaller VA improvement (p= 0.0002), >75
years and above gaining 4.2 (14.1 SD) letters and <55 years
gaining 6.6 (14.2 SD) letters. After adjustment for age group and
baseline VA each additional injection gave an improvement of
0.56(0.14) letters (p < 0.0001).
An alternative parameterisation of the data uses survival
analysis to look at time to sustained gain of ten letters, using
number of injections as a time-dependent co-variate in a Cox
proportional hazards model. This model shows that those with
better VA and those who are older are less likely to gain ten letters
and also that at each time point having had one more injection
Table 1. Numbers of patients with potential data and actual data over
three years.
Year 1 Year 2 Year 3
Total number of patients 2196 1270 506
Excluded from annual time point:
no data within 8 weeks but has
data at a further time point
228 163 58






Total analysed for annual
time points
1742 860 305








N 1742 860 305
Age at first injection
(years) (Median 25th
to 75th centile)
64 (56–73) 64 (56–72) 63 (55–72)






15 (10–21) 15 (9–21) 14 (8–21)
Injections (n) 6 (5–8) 9 (6–11) 12 (7–16)
VA at start of period
(letters) (Median
ETDRS letters)




71 (60–78) 70 (60–78) 70 (60–77)
VA gain (letters) 5 (−1 to 12) 5 (−2 to 12) 5 (−2 to 13)















increased the probability of achieving a ten-letter gain, hazard
ratio 1.10 (95% CI 1.06–1.15).
The proportion of patients with different levels of vision is given
in Fig. 1. Patients with >70 letters increased from 39% at baseline
to 56% at 1 year, 55% at 2 and 51% at 3 years, for those still under
follow-up.
We analysed which sites used a 3, 5 or 6 initial monthly injection
protocol and whether that influenced the total number of
injections given over time or the VA outcomes. (Table 3) A
three-injection loading dose protocol defined as giving three
injections 28 days apart was given in 1393/1742 (80%), with
substantial difference between centres (35–100%). Altogether 256
patients had a five-injection loading protocol, the majority in four
centres who completed this in 75–79% of cases. Only 86 patients
received a six injection loading phase, the majority of whom were
from one centre, which used this protocol in 80% of their patients.
We found no difference in the VA at 1 year regardless of the
initial treatment protocol used and the average number of
injections was the same, although there was an association with
more improvement with more injections. There was no difference
between the patients given the different initial treatment
protocols in age or duration of diabetes at first injection, however,
those on the five and six injection loading protocols had better VA
at the start (three or four more letters), so whilst there was no
difference in the gain, the VA at 1 year was better.
The number of injections during the 3 years of treatment varied
slightly depending on the starting loading strategy, but overall,
there was no statistically significant difference in the final number
of injections regardless of which loading protocol was used. Of
those who were lost to follow-up 42% had an injection at their
last visit.
Additional focal laser was administered to 5.3% in the 1st year,
10.3% in the 2nd and 13.4% in the 3rd year. An additional 259
patients, not included in our analysis as we only included those
given aflibercept alone, had been started on aflibercept but
subsequently switched to Ozurdex (241) or Iluvien (18).
Using survival modelling with loss to follow-up as the event of
interest we found that those with better baseline VA are more
likely to continue to attend (70 or more EDTRS letter compared to
<50, Hazard ratio 0.68 (0.55–0.84) and those in the oldest age
group are least likely to attend (>75 compared to <55 years,
Hazard ratio 1.28 (1.02–1.61).
The IMD was correlated with age at first injection and VA at first
injection. The most deprived were younger (p= 0.0017) and had
worse VA at first injection (p= 0.0001). The number of injections
Fig. 1 ETDRS letter score colour bands at each year time point.
Proportion of patients, who had data, with different levels of visual
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was not related to deprivation (p= 0.91). There was no correlation
between IMD and change in VA Hence the most deprived started
from a lower baseline VA and had worse vision at 1 year (p=
0.0001) Those in the most deprived group were more likely to be
lost to follow-up, 15% of the most deprived versus 10% in the less
deprived groups by end of 1 year (Log rank test p= 0.0010 (Fig. 2).
DISCUSSION
Our study found that mean VA at which treatment is started has
risen from 51 letters to 62 (Median 65) since the last RWE in DME
data were published from the UK [6]. This is in parallel with a
starting VA rise seen in clinical trials, such as 57 in RISE and RIDE
and 60 in VIVID and VISTA [3, 4].
The DRCR.net has found that eyes with lower VA at baseline
were more likely to achieve larger gains in VA but less likely to
reach near-normal VA with only 17% of eyes with 25–50 letters
reaching 72 letters or better with treatment [9]. Good starting VA
is therefore crucial for good outcomes, however, recent data
support that for those >72 ETDRS letters delaying treatment over
2 years may not actually lead to a worse outcome [10].
We found a five mean letter gain after a relatively low number
of injections compared to clinical trials in the first year (mean
no= 6). However, this was nearly double that of a previous UK
RWE report in which the mean number of injections was 3.3 [6].
This was however reported using ranibizumab before aflibercept
was available. A five letter mean gain is about half of that
observed in VIVID and VISTA. The baseline VA of our patient cohort
was marginally higher at 62 (Median 65) compared to the baseline
VA of 60 in the pivotal trials but the mean VA achieved was a
lower at 67 (Median 71) vs 70 suggesting there is room for
improvement if more injections were given. Indeed, we found that
the likelihood of gaining ten letters increased with each additional
injection. The VA in our study was tested with habitual correction
rather than refraction each time so was likely to have under-
estimated VA. In a UK prospective data collection study, which
used refracted VA, the baseline VA was 69.5 letters [11].
Retention of DME patients is problematic in most clinical
settings. In one RWE reporting on 117 patients, a gain of 4.8 and
9.6 letters were seen over 1 and 2 years, starting at 60 letters, with
5.5 injections at 1 year and a total of 8.7 at 2, however, only 31
patients had data at 2 years [12]. In the APOLLON study, a
prospective 1-year follow-up RWE study in France 147 patients
were included in the analysis but the cohort started at 402 (77
treatment naive). The baseline VA was 62.7 letters increasing by
+7.8 letters after a mean of 7.6 injections at 1 year [13].
The Fight Retinal Blindness registry reported visual gains of
+1.4 letters for 217 eyes receiving aflibercept with 70 or better VA
at baseline and +10.6 with those <65, using a mean of 8
aflibercept injections at 12 months, 21% were lost to follow-up,
compared to 10% at 1 year in our study [14].
A larger multicentre study from Japan of 2049 eyes measured a
mean gain of 2.2 letters using a mixture of treatments. For patients
just given anti-VEGF injections it was +4.5 but only 4.3 injections
were given over 2 years. This study was unable to account for
patients who did not have data at 2 years [15].
RWE reported from America from the Vestrum Health Retina
Database had 15,608 DME patient eyes in the analysis. In the 12-
month cohort, of 1379 eyes initially treated with aflibercept, the
mean 12-month improvement was +5.5 letters (95% confidence
interval [CI] +4.5 to +6.6 letters, P < 0.001) from a baseline of 57.9,
after 7.5 injections on average [16].
Recommendations by a UK expert panel on the use of
aflibercept in DME, published in a 2020 report that, “most panel
Fig. 2 Percentage lost to follow-up over time in months in relation to the index of multiple deprivation score (IMD). The IMD has been
grouped into four bands with least deprived being 0 and most 3 for the purpose of this analysis.
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members use six initial 4 weekly doses, as in Protocol T, rather
than five initial monthly doses as recommended in the Summary
of product characteristics (SmPC)” [17]. Our data show that only a
small percentage of patients received 5 or 6 four weekly injections,
either because this was not possible or not felt necessary by the
clinician or patients.
The use of additional focal laser rose from 5.3% at the end of
the first year to 13.4% at 3 years which was a lot lower than in the
DRCR.net protocol T study in which laser varied from 30–40% [5].
Loss to follow-up is a weakness of our study for assessing VA
outcomes, especially by 3 years, however, loss to follow-up rates is
an important outcome in itself as this is a very important issue for
the effectiveness of the treatment. This is a large study from 21
centres showing this is a widespread problem. Some missing data
were due to incomplete EMR system use in some centres. Missing
annual data were partly due to patients not attending regularly or
not needing to be seen within the 8-week anniversary window.
We found that attrition was not random with an increased rate for
those starting with lower vision and being of older age also
patients were more likely to attend if they were actively having
injections. By 3 years a proportion of patients may have been
discharged back to diabetic eye screening if they were stable.
Death was recorded in 119 (4%) but this may have been an
underestimate due to variation in how the EMR links to other
records. Full data on comorbidities were not available, and these,
especially strokes and heart attacks, could considerably change
attendance and treatment frequency.
We found that those in the most deprived areas were also more
likely to be lost to follow-up, be younger and have worse vision at
the first injection. On the positive side, the number of injections
and the change in VA were not related to deprivation suggesting
that once aflibercept treatment was started, patient care was not
compromised as a consequence of deprivation status. A previous
large study of 79,775 patients in the UK also found an association
between later presentation with worse VA for patients with
diabetic retinopathy who were from more deprived areas [8]. Our
data show that part of the differences in VA outcomes amongst
the centres included in this study can be explained by the
variations in the age profile of patients, their initial VA and the
deprivation levels. Further work is needed to understand reasons
for non-adherence to visit schedules and to find solutions [18, 19].
SUMMARY
What was known before
● Randomised clinical trials of aflibercept for DME show it can
improve vision. In clinical practice, the same results may not
be achieved
What this study adds
● There was variation between centres for Index of multiple
deprivation, age and baseline visual acuity. These factors affected
the visual acuity outcomes. The provision of Initial injection
protocols of 3–6 monthly injections varied greatly between
centres but did not affect the mean Visual acuity at 1 year.
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